The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study
Abstract
BACKGROUND: The long-term treatment of Parkinson disease (PD) may be complicated by the development of levodopa-induced dyskinesia. Clinical and animal model data support the view that modulation of cannabinoid function may exert an antidyskinetic effect. The authors conducted a randomized, double-blind, placebo-controlled crossover trial to examine the hypothesis that cannabis may have a beneficial effect on dyskinesia in PD. METHODS: A 4-week dose escalation study was performed to assess the safety and tolerability of cannabis in six PD patients with levodopa-induced dyskinesia. Then a randomized placebo-controlled crossover study (RCT) was performed, in which 19 PD patients were randomized to receive oral cannabis extract followed by placebo or vice versa. Each treatment phase lasted for 4 weeks with an intervening 2-week washout phase. The primary outcome measure was a change in Unified Parkinson's Disease Rating Scale (UPDRS) (items 32 to 34) dyskinesia score. Secondary outcome measures included the Rush scale, Bain scale, tablet arm drawing task, and total UPDRS score following a levodopa challenge, as well as patient-completed measures of a dyskinesia activities of daily living (ADL) scale, the PDQ-39, on-off diaries, and a range of category rating scales. RESULTS: Seventeen patients completed the RCT. Cannabis was well tolerated, and had no pro- or antiparkinsonian action. There was no evidence for a treatment effect on levodopa-induced dyskinesia as assessed by the UPDRS, or any of the secondary outcome measures. CONCLUSIONS: Orally administered cannabis extract resulted in no objective or subjective improvement in dyskinesias or parkinsonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Self-citationMeasuring Health: A Guide to Rating Scales and Questionnaires
Hyett, K., & Mills, T. (2006) · Australian Health Review · Cited by 632
The McGill Pain Questionnaire: From Description to Measurement
Melzack, R., & Raja, S. N. (2005) · Anesthesiology · doi:10.1097/00000542-200507000-00028 · Cited by 484
Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD
Volkmann, J., Allert, N., Voges, J., Weiss, P. H., Freund, H.-J., & Sturm, V. (2001) · Neurology · doi:10.1212/wnl.56.4.548 · Cited by 425
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001) · Neurology · doi:10.1212/wnl.57.11.2108 · Cited by 349
di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R., & Brotchie, J. M. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1432 · Cited by 303
Goetz, C. G., Stebbins, G. T., Shale, H. M., Lang, A. E., Chernik, D. A., Chmura, T. A., Ahlskog, J. E., & Dorflinger, E. E. (1994) · Movement Disorders · doi:10.1002/mds.870090403 · Cited by 276
Amantadine for Levodopa-Induced Dyskinesias: A 1-Year Follow-up Study
Metman, L. V., Del Dotto, P., LePoole, K., Konitsiotis, S., Fang, J., & Chase, T. N. (1999) · Archives of Neurology · doi:10.1001/archneur.56.11.1383 · Cited by 235
Crawley, J. N., Corwin, R. L., Robinson, J. K., Felder, C. C., Devane, W. A., & Axelrod, J. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90230-q · Cited by 231
Control of the cell survival/death decision by cannabinoids
Guzmán, M., Sánchez, C., & Galve-Roperh, I. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090000177 · Cited by 223
Cited by
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Ambulatory monitoring of freezing of gait in Parkinson’s disease
Moore, S. T., MacDougall, H. G., & Ondo, W. G. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.08.023 · Cited by 526
Hill, K. P. (2015) · JAMA · doi:10.1001/jama.2015.6199 · Cited by 508
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460
Adverse effects of medical cannabinoids: a systematic review
Wang, T., Collet, J.-P., Shapiro, S., & Ware, M. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071178 · Cited by 357
Metadata
- Authors
- Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S. G., Fox, P., Wright, D., Hobart, J., & Zajicek, J. P.
- Venue
- Neurology
- Published
- 2004-10-12
- Volume
- 63
- Issue
- 7
- Pages
- 1245-1250
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2111333842
- Cited by
- 286
- References
- 25
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study. https://app.cochat.ai/papers/10.1212/01.wnl.0000140288.48796.8e
- The paper
- Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S. G., Fox, P., Wright, D., Hobart, J., & Zajicek, J. P. (2004). Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study. Neurology. https://doi.org/10.1212/01.wnl.0000140288.48796.8e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.